The FDA revoked emergency use of the malaria drug hydroxychloroquine for COVID-19 - Israel doesn't follow

The FDA revoked emergency use of the malaria drug hydroxychloroquine for COVID-19 on Monday.
In March, President Donald Trump revealed he is taking hydroxychloroquine.
Previously the drug was approved by the FDA for the treatment of malaria and rheumatoid arthritis — and may have serious side effects.
In a letter, the FDA revoked the EUA for emergency use of HCQ and CQ to treat COVID-19, pursuant to section 564(g)(2) of the Act.
"FDA has concluded that, based on this new information and other information discussed in the attached memorandum, it is no longer reasonable to believe that oral formulations of HCQ and CQ may be effective in treating COVID-19, nor is it reasonable to believe that the known and potential benefits of these products outweigh their known and potential risks,” the FDA said. 
Why It's Important: Hydroxychloroquine is produced by Teva Pharmaceutical Indus (NYSE: TEVA) and Mylan (NASDAQ: MYL). The compound that was being targeted by health researchers is called hydroxychloroquine and is sold by Teva under the brand name Plaquenil.
In March, Teva said it had donated 6 million doses of hydroxychloroquine sulfate to hospitals around the U.S.
One of the difficulties facing American investors during the COVID-19 outbreak has been separating fact from fiction, rumor from truth and speculation from confirmation.

Hadassah Ein Kerem Hospital is not excited about the FDA decision and a new study at Hadassah Ein Kerem Hospital is testing the effectiveness of hydroxylchloroquine drug in preventing infection in Corona.
The aforementioned drug that is originally used to treat malaria, and much of what President Trump is talking about, has so far not been effective in treating people who have already been in Corona, and has even been withdrawn from use as a known drug to treat Corona by the FDA.
However, in the new study in Hadassah that began two weeks ago under the management of Prof. Alon Moses and Prof. Yossi Karco, an experiment on hydroxycloroquine is being conducted as a preventive drug to treat people who have been exposed to a coronated patient, but have not yet contracted the virus. These are mainly family members of verified patients. Today, approximately 20% to 25% of the family members of a verified patient are also infected with the virus. The success of the trial means a significant reduction in the infection rate among people exposed to a verified patient.
The apparent logic of giving the drug * before * infection is due to the fact that the mechanism of action of hydroxychloroquine is to prevent the virus from entering the cell. If the drug is already in the tissue * before * the virus infiltration, the process of cell infection can be avoided.
If the study proves the efficacy of hydroxychloroquine as a prophylactic, it could be a breakthrough in significantly reducing the morbidity of the corona in the public, in the middle state as long as there is no effective vaccine for the virus.
To date, one study has published that tested this drug as a preventive drug, and its results did not indicate that it is effective for this purpose. But Hadassah's researchers say this study was methodologically flawed and therefore does not necessarily prove that this drug is worthless.
Hadassah researchers want to reach 1,000 people (500 who will take the drug, and another 500 as the control group), and an attempt is now underway to locate family members of verified patients who will take part in the study. Preliminary results are expected in about two months.